Top 5 Healthcare Equipment Companies To Invest In 2014

The truth will make you sick. Technically it's public knowledge, but I can tell you -- it's Congress' dirty little secret.

Congress is rich. Unbelievably rich. And until just recently, insider trading laws didn't apply to Congress.

I don't know which is worse: The fact that insider trading was legal for some of our nation's wealthiest politicians... or that Congress refused to do anything about it for decades.

"A few lawmakers proposed a bill that would prevent members and employees of Congress from trading securities based on nonpublic information they obtain. The legislation has languished since 2006," according to The Wall Street Journal.

 

That was, the legislation languished until "60 Minutes" -- one of the most respected investigative journalism programs on television -- dedicated a segment to the issue. Here's a portion of what they had to say...

Hot Solar Stocks To Own Right Now: Citadel Capital SAE (CCAP)

Citadel Capital SAE is an Egypt-based company engaged in the private equity investment activities. The Company manages an investment portfolio that consist of 19 Opportunity-Specific Funds (OSFs), which controls entities platform distributed across 12 countries in the Middle Eastern and North African markets, and span 14 industrial sector such as energy, cement manufacturing, solid waste management, real estate, mining, agricultural, glass manufacturing, transportation and metallurgy. Its OSFs entities include Asec Holding, Ascom Geology and Mining SAE, Nile Logistics, Rift Valley Railways, Gozour, Wafra, Nopc / Rally Energy Group, Nile Valley Petroleum Ltd, Egyptian Refining Company, Taqua Arabia, GlassWorks and Finance Unlimited, among others. On December 9, 2012, the Company announced that it has sold 100% of its interest in National Petroleum Company Egypt Limited (NPC Egypt), a wholly owned portfolio company, to Sea Dragon Energy Inc. Advisors' Opinion:

• [By Julia Leite]

  Declines provided an opportunity for ��rofit taking��for ��hort term players who bought in the last week or so,��Julian Mayo, who helps manage $2.5 billion in emerging-market assets as the co-chief investment officer at Charlemagne Capital Ltd. (CCAP) in London, said by e-mail. ��fter a 5 to 10 percent gain in some emerging markets in such a short time, some correction is always likely.��

• [By Joshi Madhavi]

  Charlemagne Capital Limited (CCAP) is an established asset management group in the UK with an exclusively emerging markets focus and bottom-up stock picking process. The business is cyclical with fortunes linked to emerging market performance. The company�� strategy is to grow each category within its broad fund range: mutual funds, hedge funds, specialist funds and institutional products.

Top 5 Healthcare Equipment Companies To Invest In 2014: Ruby Tuesday Inc.(RT)

Ruby Tuesday, Inc., together with its subsidiaries, develops, operates, and franchises casual dining restaurants in the United States, Puerto Rico, Guam, and internationally. The company operates its restaurants under the Ruby Tuesday brand, as well as owns and operates one Marlin & Ray?s, one Truffles, and two Wok Hay casual dining restaurants. As of August 30, 2011, it owned and operated 746 Ruby Tuesday restaurants; and 43 domestic and 52 international franchisees operated restaurants. The company was founded in 1920 and is based in Maryville, Tennessee.

Advisors' Opinion:

• [By Sean Williams]

  To begin with, poor economic growth conditions act to keep consumers in their homes and away from restaurants. Higher payroll taxes, for instance, are reducing consumers' budgets and forcing some to eat out less. This has been one of the main setbacks for restaurant chain Ruby Tuesday (NYSE: RT  ) , which has tried boosting its marketing budget on numerous occasions and emphasizing its specials to drive traffic, but has been largely unsuccessful in doing so.

Top 5 Healthcare Equipment Companies To Invest In 2014: Echo Therapeutics Inc (ECTE)

Echo Therapeutics, Inc. (Echo), incorporated on September 10, 2007, is a transdermal medical device company. The Company is developing Prelude SkinPrep System (Prelude) as a technology to allow for painless and skin permeation that enable both analyte extraction and needle-free drug delivery. The Company is developing its Symphony CGM System (Symphony) as a non-invasive, wireless continuous glucose monitoring (CGM) system for use in hospital critical care units and for people with diabetes. The Prelude SkinPrep System (Prelude), a component of its Symphony CGM System, allows for skin permeation that enables extraction of analytes such as glucose. Prelude�� platform skin preparation technology also allows for needle-free, transdermal drug delivery.

Symphony CGM System

The Symphony CGM System incorporates a Prelude skin preparation device, transdermal sensor, wireless transmitter and data display monitor. When the electro-chemical glucose sensor is placed on the prepared site, it uses glucose oxidase to generate a continuous current that is proportional to the concentration of blood glucose in the vessels beneath the epidermis. The signals are then wirelessly transmitted to a remote monitor. The monitor, calibrated periodically with a reference blood glucose measurement, converts the data to a glucose measurement based on the reference value. The monitor displays glucose readings and also contains customizable early-warning alarms for hypo- or hyperglycemia.

Prelude SkinPrep System

The Company is developing Prelude as a transdermal skin preparation device for Symphony to improve the access to the interstitial fluids and the flow of molecules across the protective membrane of the stratum corneum, the outmost protective layer of the skin. Prelude incorporates the Company's skin abrasion control technology into a hand-held device used to prepare a small area of the skin. The non-invasive sensor is applied to this prepared area in order to measure the in! terstitial glucose levels.

Specialty Pharmaceuticals

The Company�� specialty pharmaceuticals pipeline is based on itsAzone transdermal drug reformulation technology. AzoneTS is a nontoxic, nonirritating skin penetration that is intended to enable topical application of food and drug administration (FDA) -approved drugs, including pharmaceutical products that previously could only be administered systemically. Its advanced drug candidate is Durhalieve, an AzoneTS formulation of triamcinolone acetonide, medium potency corticosteroid approved by the FDA for treatment of corticosteroid-responsive dermatoses. AzoneTS increases lipid membrane fluidity in the stratum corneum layer of the skin, thereby decreasing resistance to topically applied therapeutics.

The Company competes with Roche, Johnson & Johnson, Bayer, Abbott Laboratories , DexCom, Inc., Medtronic, Inc., Edwards Lifesciences Corporation, Optiscan Biomedical Corp., Medtronic, Glysure, Glumetrics Inc., Maquet and A. Menarini Diagnostics S.r.l.

Advisors' Opinion:

• [By Roberto Pedone]

  Another under-$10 health care player that's quickly moving within range of triggering a major breakout trade is Echo Therapeutics (ECTE), which is a transdermal medical device company with skin permeation technology. This stock has been destroyed by the bears so far in 2013, with shares off huge by 70%.

  If you take a look at the chart for Echo Therapeutics, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of $2.14 to its intraday high of $3.06 a share. During that uptrend, shares of ECTE have been consistently making higher lows and higher highs, which is bullish technical price action. That move has pushed shares of ECTE back above its 50-day moving average at $2.65 a share, and it's just starting to push ECTE into breakout territory, since the stock has cleared some key near-term overhead resistance levels at $2.98 to $2.99 a share. That move is quickly pushing shares of ECTE within range of triggering an even bigger breakout trade.

  Market players should now look for long-biased trades in ECTE if it manages to break out above some major near-term overhead resistance at $3.30 a share with high volume. Look for a sustained move or close above that level with volume that registers near or above its three-month average volume of 211,103 shares. If that breakout triggers soon, then ECTE will set up to re-test or possibly take out its next major overhead resistance levels at $4 to $4.50 a share, or possibly even $5 to $6 a share.

  Traders can look to buy ECTE off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $2.65 a share, or right below more near-term support at $2.50 a share. One can also buy ECTE off strength once it clears $3.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Bryan Murphy]

  Truth be told, Echo Therapeutics Inc. (NASDAQ:ECTE) doesn't look like a particularly impressive stock right now. At $2.92 per share, ECTE is just trading right around where it was a few days ago, not to mention a few weeks ago. And, without any real "news" from the company in months, it's tough to think the market's going to be getting excited about the stock anytime soon. When you take a closer look at Echo Therapeutics though, a few subtle-but-compelling clues start to appear.

Top 5 Healthcare Equipment Companies To Invest In 2014: Sedex Mining Corp (SDN)

Sedex Mining Corp. is a resource exploration-stage company. The Company is engaged in the acquisition and exploration of exploration and evaluation assets. The Company�� Elephant Lake property is approximately 100 kilometers south of Timmins Ontario which has produced over 67 million ounces of gold. The Nickel North property lies approximately 22 kilometers northwest of the Kidd Creek Mine. The Kidd Creek Mine has produced over 115,000,000 tons of ore averaging 2.2% copper (Cu), 7.25% zinc (Zn), 0.28% lead (Pb) and 147.43 g/t silver (Ag)). Nordica property lies 55 kilometers southeast of Timmins, a prolific gold producing camp with. The property also lies approximately 24 kilometers southeast of Langmuir Township, a well known nickel belt with four known nickel deposits and GCR's recent W4 nickel discovery. Advisors' Opinion:

• [By Eshna Basu]

  Juniper is increasingly becoming active in the "software defined networking" (SDN) field to make its presence felt in the booming data center space, where it is still a small player.